Effect of a Remotely Delivered Weight Loss Intervention in Early-Stage Breast Cancer: Randomized Controlled Trial.

Limited evidence exists on the effects of weight loss on chronic disease risk and patient-reported outcomes in breast cancer survivors. Breast cancer survivors (stage I-III; body mass index 25-45 kg/m) were randomized to a 12-month, remotely delivered (22 telephone calls, mailed material, optional text messages) weight loss (diet and physical activity) intervention ( = 79) or usual care ( = 80). Weight loss (primary outcome), body composition, metabolic syndrome risk score and components, quality of life, fatigue, musculoskeletal pain, menopausal symptoms, fear of recurrence, and body image were assessed at baseline, 6 months, 12 months (primary endpoint), and 18 months. Participants were 55 ± 9 years and 10.7 ± 5.0 months post-diagnosis; retention was 81.8% (12 months) and 80.5% (18 months). At 12-months, intervention participants had significantly greater improvements in weight (-4.5% [95%CI: -6.5, -2.5]; < 0.001), fat mass (-3.3 kg [-4.8, -1.9]; < 0.001), metabolic syndrome risk score (-0.19 [-0.32, -0.05]; = 0.006), waist circumference (-3.2 cm [-5.5, -0.9]; = 0.007), fasting plasma glucose (-0.23 mmol/L [-0.44, -0.02]; = 0.032), physical quality of life (2.7 [0.7, 4.6]; = 0.007; Cohen's effect size () = 0.40), musculoskeletal pain (-0.5 [-0.8, -0.2]; = 0.003; = 0.49), and body image (-0.2 [-0.4, -0.0]; = 0.030; = 0.31) than usual care. At 18 months, effects on weight, adiposity, and metabolic syndrome risk scores were sustained; however, significant reductions in lean mass were observed (-1.1 kg [-1.7, -0.4]; < 0.001). This intervention led to sustained improvements in adiposity and metabolic syndrome risk.